Making the Case Against Gene Patents

Simoncelli, Tania; Park, Sandra S.

doi:10.1162/posc_a_00161

Cited by 7 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The monopoly ended at the U.S. Supreme Court, when Myriad lost an epic patent battle against the American Civil Liberties Union (132). The following month, August 2013, Myriad filed the first of several lawsuits against seven competitors, all of which ended when the Court of Appeals for the Federal Circuit invalidated Myriad’s patents in December of 2014.…”

Section: Emergence Of the Global Alliance For Genomics And Healthmentioning

confidence: 99%

Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance

Cook-Deegan

Ankeny

Jones

2017

Annu. Rev. Genom. Hum. Genet.

View full text Add to dashboard Cite

The Human Genome Project modeled its open science ethos on nematode biology, most famously through daily release of DNA sequence data based on the 1996 Bermuda Principles. That open science philosophy persists, but daily, unfettered release of data has had to adapt to constraints occasioned by the use of data from individual people, broader use of data not only by scientists but also by clinicians and individuals, the global reach of genomic applications and diverse national privacy and research ethics laws, and the rising prominence of a diverse commercial genomics sector. The Global Alliance for Genomics and Health was established to enable the data sharing that is essential for making meaning of genomic variation. Data-sharing policies and practices will continue to evolve as researchers, health professionals, and individuals strive to construct a global medical and scientific information commons.

show abstract

Section: Emergence Of the Global Alliance For Genomics And Healthmentioning

confidence: 99%

Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance

Cook-Deegan

Ankeny

Jones

2017

Annu. Rev. Genom. Hum. Genet.

View full text Add to dashboard Cite

show abstract

“…One such attempt was by the NIH to patent products of the Human genome project by filing an application of 350 gene segments. However, USPTO has rejected the patenting of these genes segments (Simoncelli & Park, 2015…”

Section: The Emergence Of Patent Law In the Biotechnology Industrymentioning

confidence: 99%

Patent Portfolio Constructionism for Biopharmaceuticals Lifecycle Management

Almutairi¹

View full text Add to dashboard Cite

Biopharmaceutical inventions challenge the patent system's ability to provide sufficient market exclusivity for new and emergent technologies and create a competitive advantage. Recently, the theory of 'the patent portfolio' has emerged to explain modern views of the value of exclusivity. This thesis aims to address the increasing complexity and nature of the 'private value' of patent portfolios and the related companies' patenting strategies in the biopharmaceutical industry. The inconsistent understanding of, and the underlying linkage between, the 'private value' of patent portfolios and patenting strategies often results in reduced efficiency in drug lifecycle management. In an attempt to characterize companies' patenting strategies, the logic behind the influence of patent portfolio attributes in the process of 'private value' creation has been examined. This thesis attempts to develop a novel conceptual model of 'private value' and advance the understanding of patent portfolios in therapeutic biologics. The model of 'private value' integrates a conceptual framework of the portfolio attributes of Scale, Technology Diversity, Total Citations and Age. The conceptual model was empirically investigated using data sources of patent portfolios for 116 FDA approved therapeutic biologics. Portfolio 'private value' attribute variances were employed to identify the incremental 'private value' constructs of patent portfolios using Principal Component Analysis. In addition, given the diversity of patenting strategies, an investigation of how patenting behaviours across biopharmaceutical companies influence the 'private value' of patent portfolios in the drug lifecycle management process was conducted. The findings in this thesis contribute to the understanding of the 'private value' in biopharmaceutical lifecycle management (LCM) in a number of ways. The analysis shows that the 'private value' of patent portfolios is most closely related to the technical scope constructs of 'Uncertainty' and 'Substitution'. The results also indicate that the attributes that contribute most to 'private value' are Scale, Total Citations, and Age with Scale being the most important. On the basis of my research, I suggest the consideration of alternative attributes for patent portfolio theory, i.e. the 'Technology Strength' and 'Lifetime'. Moreover, the synergy of both proposed attributes is as important as the factors themselves. iii Three patent clusters for patenting patterns were identified. The cluster taxonomy shows the impact of portfolio characteristics on the selected patenting strategies. The observed patenting strategies confirm the dominance of offensive strategies to increase the lifecycle of therapeutic biologics. Offensive blockage strategies are invariably connected with the creation of early 'Uncertainty' and later 'Substitution' constructs of 'private value'. The findings suggest that the most successful configuration of patent portfolios is characterised by targeted patenting strategies that are in alignment with the desi...

show abstract

Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese Press

Lin

Kamenova

2020

ABR

View full text Add to dashboard Cite

Making the Case Against Gene Patents

Cited by 7 publications

References 10 publications

Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance

Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance

Patent Portfolio Constructionism for Biopharmaceuticals Lifecycle Management

Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese Press

Contact Info

Product

Resources

About